Art

J-GLOBAL ID：202102284114626850   Reference number：21A0137840

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

非小細胞肺癌患者におけるデュルバルマブ誘発性免疫関連肝炎

Author (11)： Nakamura Masakatsu (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Otsuka Toshimi (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Hayashi Ranji (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Horita Tomoe (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Ota Masafumi (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Sakurai Naoko (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Takano Hikaru (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Hayashi Tasuku (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Kumagai Motona (Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan) ,  Yamada Sohsuke (Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan) ,  Arisawa Tomiyasu (Department of Gastroenterology, Kanazawa Medical University, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 59  Issue： 21  Page： 2711-2717(J-STAGE)  Publication year： 2020 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *Durvalumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0137840&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (3)： immune-related hepatitis ,  durvalumab ,  non-small cell lung cancer

JST classification (4)： Clinical oncology in general  (GE03010Y) ,  Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Digestive system diseases  (GH03000W) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (2)： Paclitaxel ,  Methylprednisolone

Reference (20)：

• 1. Guidelines for medical treatment of lung cancer 2019 edition Japan Lung Cancer Society.
• 2. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stageIII non-small-cell lung cancer. N Engl J Med 377: 1919-1929, 2017.
• 3. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379: 2342-2350, 2018.
• 4. Osta B. El, Hu F, Sadak R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119: 1-12, 2017.
• 5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 366: 2517-2519, 2012.

Terms in the title (5)： 非小細胞肺癌 ,  患者 ,  デュルバルマブ ,  免疫 ,  肝炎